GlaxoSmithKline (GSK) is to acquire Genelabs Technologies for US$57 M in a deal which will boost GSK’s hepatitis C virus (HCV) pipeline. With growing patient numbers and poor treatment options, there is a high unmet need for new HCV therapies - and therefore huge rewards to be made from developing a successful new treatment.